Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $89.90

Janux Therapeutics, Inc. (NASDAQ:JANX) has earned a consensus recommendation of “Buy” from the twelve analysts that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, ten have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $89.90.

Several equities analysts have recently commented on JANX shares. Scotiabank upped their price objective on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 4th. BTIG Research upped their price target on Janux Therapeutics from $82.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, December 3rd. Stifel Nicolaus lifted their price objective on Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Leerink Partners increased their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $200.00 target price on shares of Janux Therapeutics in a research report on Wednesday, December 11th.

Insider Transactions at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. bought 1,200,000 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were acquired at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the transaction, the director now owns 9,317,246 shares of the company’s stock, valued at approximately $416,946,758.50. The trade was a 14.78 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David Alan Campbell sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $53.54, for a total value of $1,338,500.00. Following the sale, the chief executive officer now owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. The trade was a 8.14 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 92,801 shares of company stock valued at $5,174,735. Insiders own 29.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of JANX. Summit Securities Group LLC acquired a new position in Janux Therapeutics in the second quarter valued at $29,000. Amalgamated Bank boosted its position in shares of Janux Therapeutics by 61.1% in the 2nd quarter. Amalgamated Bank now owns 970 shares of the company’s stock valued at $41,000 after purchasing an additional 368 shares during the period. Plato Investment Management Ltd acquired a new stake in shares of Janux Therapeutics in the 2nd quarter valued at about $42,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after buying an additional 339 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Janux Therapeutics during the second quarter worth approximately $151,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $54.10 on Friday. Janux Therapeutics has a 52 week low of $7.79 and a 52 week high of $71.71. The stock’s fifty day moving average is $54.43 and its two-hundred day moving average is $47.43.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The company had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business’s quarterly revenue was down 82.6% on a year-over-year basis. On average, equities research analysts anticipate that Janux Therapeutics will post -1.35 EPS for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.